A judge has granted F. Hoffman La-Roche’s request for a temporary order blocking Sandoz from making or selling a biosimilar version of its patented biologic used to treat various cancers and rheumatoid arthritis.
Triclops Technologies has filed an appeal less than one month after the Federal Court dismissed its case alleging a rival infringed its patent for an industrial machine safety system that uses laser fields to detect hazards, but found the patent was valid.
The Australian Manuka Honey Association has introduced a new standard for verifying authentic, Australian manuka honey, as the group continues its battle with New Zealand over intellectual property rights to the expensive superfood.
Two GPS tracking patents at the heart of a David vs. Goliath battle between Domino’s and a Sydney-based startup were foreshadowed by a patent owned by Uber, the pizza chain giant told a court Friday.
IP Australia has denied liquor producer Patron Spirits’ opposition to rival Fernbrew’s trade mark for Pirate Bay Rum, saying the mark was not likely to be confused with Patron’s Pyrat brand of rum.
IP Australia has ruled in part that cheese branded with the Asiago label need not be manufactured in the Asiago region in Italy, striking down an opposition to a trade mark filed by cheese producer Sartori Company.
Three generic drug manufacturers cannot claim damages for an injunction barring the release of cheaper versions of Effexor-XR, even if the injunction was later overturned, pharmaceutical giant Wyeth told a judge on day two of a six-week trial over its blockbuster antidepressant.
Hilton Worldwide — which owns New York’s iconic Waldorf Astoria hotel — has won a bid to block an Australian serviced apartments provider from registering trade marks for the phrase “Waldorf Apartments”.
The High Court has rejected a bid by biopharmaceutical company Samsung Bioepis Australia to challenge a ruling granting Pfizer preliminary discovery for a potential patent infringement case over autoimmune drug Enbrel.
Pharmaceutical giant Wyeth’s has launched an “ambush” at the beginning of a trial after a nine-year long battle against several generic drug makers, alleging infringement of a second patent for its blockbuster Effexor-XR, a judge heard Monday.